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ABSTRACT 
Objective: Aim of this study was to develop the topical delivery containing ivabradine hydrochloride (IVH) loaded transpersonal gel for 
symptomatic treatment of chronic stable angina pectoris in coronary artery disease.  
Methods: Different hydrophilic-lipophilic balance (HLB) values of surfactants-tween-80, span-80 and sodium deoxycholate (SDC) were investigated 
to prepare transfersomes (TFs)respectively, with different concentration of soya phosphatidylcholine and 10% v/v ethanol in phosphate buffer 
solution (pH 6.8) by conventional rotary evaporation sonication method. The prepared formulations were evaluated for percentage entrapment 
efficiency (%EE), deformability index (DI), turbidity, vesicle shape and size, in vitro drug release study and stability. SEM was done on selected 
formulation F8 and liposome formulation (LF). Gel was prepared by using carbopol-940 as a gelling agent with propylene glycol, polyethylene glycol 
solution as permeation enhancer by 32 factorial design optimization methods. The developed gel was evaluated for pH, viscosity, drug content, ex-
vivo permeation studies and stability studies of TFs-gel. This was compared with LF-gel prepared by same procedure. 
Results: Maximum % EE (78.4±0.94), suitable vesicular size (128.6 nm) and maximum DI (34.9±1.9) was found in TFs-TW-80 and selected for gel 
development. In vitro drug release data from TFs-TW-80, plain drug solution and liposomal formulation (LF) revealed that % cumulative drug 
released in TFs-TW-80 was found maximum (89.5±0.12 %) in 20 min than others. It was 2.1 times higher than LF and 3.3 times higher than the 
plain drug. SEM study showed spherical shape of vesicles. The drug contents in the TFs and LF gels were found to be 92 to 95%w/w. Partition 
coefficient for TFs-loaded gel was 1.04±0.03. Ex vivo permeation study from hairless rat skin showed that permeation of drug is described by firstly 
first-order kinetics than zero-order kinetics. The drug released from TFs-gel was found to be 1.7 times higher than LF-gel and about 1.9 times higher 
than plain drug. Flux from TFs-gel was 2.04 times greater than LF-gel and 3.28 times more than plan drug. Stability studies indicated that suitable 
storage condition for developed gel was temperature 25 °C or less, where the pH, potency and therapeutic efficacy of formulations remain constant.  
Conclusion: Thus, transdermal route has become one of the most successful and innovative focus for research in drug delivery of IVH loaded TFs-
TW-80 to increase stability and bioavailability. 
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INTRODUCTION 
IVH is an Anti-anginal drug and selective hyperpolarization-activated 
cyclic nucleotide-gated channels inhibitor that lowers the heart rate 
and used in the treatment of chronic stable angina in patients unable 
to take beta-adrenergic blockers and in the treatment of heart failure. 
IVH is water-soluble, biological half-life of about two hours, lower 
melting point than 200 °C and low bioavailability of 40%. Therefore, it 
was found a suitable candidate for transdermal drug delivery systems 
(TDDS). These are topically administered medicaments in the form of 
patches or semisolids, which can be applied to the intact skin to 
deliver the drug through the skin at a controlled rate to the systemic 
circulation. It improves therapeutic efficacy and safety of drugs [1]. In 
the last two decades this system have been developed in order to 
avoid hepatic first-pass effect and to improve drug bioavailability and 
to overcome the side-effects associated with oral route. The first 
transdermal patch was approved in 1981 by FDA [2]. In recent years, 
vesicular based drug delivery system is developed in order to improve 
the bioavailability of hydrophilic as well as lipophilic drugs. These 
vesicular systems are promising systems for transdermal drug 
delivery as they act as vehicles or as permeation enhancers for drugs 
[3]. There are various strategies have been used to augment the 
transdermal delivery of bioactive products. The vesicular system 
transfersomes (TFs) loaded gel was selected for present work in 
comparison with liposomal gel [4]. TFs when applied to skin under 
suitable condition, they can transfer 0.1 mg of lipid per hour and cm2 
area across. The mechanism for penetration is the generation of 
osmotic gradient due to evaporation of water while applying the 
transfersomes on the skin surface. The transport of these elastic 
vesicles is thus independent of concentration. The trans-epidermal 
hydration provides the driving forces for transport of the vesicles [5]. 
Elastic polymers are good candidate for topical delivery to maintain 
stability of drug. Carbopol-940 has excellent thickening efficiency at 
high viscosity at very low concentrations (less than 1%). It gives clear 
transparency in aqueous or hydro-alcoholic solutions suitable for use 
in cosmetics and topical applications. Some permeation enhancers like 
surfactants, polyethylene glycol (PEG), propylene glycol (PG) etc. are 
used. Present investigation of TFs preparation of Ivabradine 
hydrochloride by transdermal route is an attempt to avoid first-pass 
metabolism of drug and release of drug in a more controlled fashion to 
improve the bioavailability to stabilize the encapsulated drug. 
MATERIALS AND METHODS 
The sample of IVH used in this study was generously provided by 
Ind-swift Ltd., Chandigarh, India as a gift sample. Carbopol-940 and 
PG (from Himedia) Mumbai were purchased. All other chemicals and 
solvents used in this study were of analytical grade. Freshly distilled 
water was used throughout the work. 
Estimation of IVH 
For estimation of IVH ultraviolet (UV) spectrophotoscopic (UV-2400 
PC series, Shimadzu, Japan) method was used, which was based on 
the measurement of absorbance at 286.0 nm in phosphate buffer 
(pH 6.8) [6]. The concentration was obtained from corresponding 
absorbance using calibration curve prepared in the concentration 
range 10-55µg/ml. The absorbance can be determined by using an 
equation developed by this method as y = 0.018x+0.014.  
Formulation of IVH-loaded TFs 
These were prepared by the conventional rotary evaporation 
sonication method [7]. Precisely, ratio of soya phosphatidylcholine: 
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surfactants {span-80, tween-80 and sodium deoxycholate (SDC)} 
were taken in different concentration ratio (95:05, 90:10, 85:15, 
80:20 and 75:25) in a fifteen clean, dry, round bottom flasks 
respectively (labelled as F1-F15). In each flask 20 ml chloroform: 
methanol mixture (2:1v/v) was added gradually by shaking slowly 
to obtain a dispersion. The organic solvent was removed by rotary 
evaporator above the lipid transition temperature (Bucci type rotary 
evaporator, Zenith engg, India). Final traces of solvent were 
removed under vacuum overnight. The deposited lipid film was 
hydrated with 10% v/v ethanol in phosphate buffer solution (pH 6.8) 
by rotation at 60 rpm for one hour at room temperature. The resulting 
vesicles were swollen for two hours at room temperature to get large 
multi-lamellar vesicles. The thick suspension thus obtained was 
broken by vortexing (Vortex shaker, Jyoti scientific industry, India). 
The resulting suspension was sonicated (Soniwel, India) for 30 min at 
4 °C for achieved desired vesicle size. The sonicated vesicles were 
extruded through a sandwich of 200 nm and 450 nm polycarbonate 
membranes (Millipore). The liposomes (soya phosphatidylcholine: 
cholesterol, 7:3 molar ratio) that act as a control in the present study 
were prepared by the same method as described above. IVH was 
incorporated into all vesicle formulations (F1-F15) and in liposomal 
formulation (LF) at a saturated concentration to obtain equal 
thermodynamic activities. Table 1 showed the formulation 
composition of TFs. 
Characterization of TFs vesicle 
Turbidity measurement  
10 ml of TFs from each formulation was diluted with 5 ml of distilled 
water and sonicated for 5 min. the turbidity was appeared and 
observed visually (physical appearance).  
Mean vesicle size measurement 
Vesicles without sonication were visualized by using an electron 
optical microscope (Olympus, India). A thin film of TFs was spread 
on a slide and a coverslip was placed over it and observed under the 
optical microscope using 45X lens [8]. 
Determination of entrapment efficiency 
Vesicle preparations were kept overnight at 4 °C and ultra-
centrifuged (Remi Equipments, Mumbai, India) at 22000 rpm at a 
temperature of 4 °C for 2 h, whereupon the pellets of transfersomes 
and the supernatant containing free drug were obtained. The 
transfersomes pellets were washed again with distilled water to 
remove any unentrapped drug by centrifugation. The combined 
supernatant was analyzed for the drug content after suitable 
dilution with phosphate buffer solution (pH 6.8) by measuring 
absorbance at 286 nm using UV-visible spectrophotometer 
(Shimadzu-1700, Japan). Same procedure was adopted with 
liposomal formulation. Encapsulation efficiency was calculated 
according to equation [9] as follows- 





A1= Amount of drug added initially (Total drug),  
A2= Amount of drug determined in the filtrate by 
spectrophotometrically (Diffused drug),  
(A1–A2) = represents the amount of drug entrapped in the 
formulation.  
Determination of deformability index (DI) 
The deformability study was done for all vesicular formulations 
against the standard liposome preparations. The elasticity of 
transfersomes vesicles was measured by the extrusion method. The 
transfersomes and liposomes formulations were extruded through 
filter membrane (pore size diameter 100 nm), using a stainless steel 
filter holder having 50 mm diameter by applying 2.5 bar pressure. 
The quantity of vesicles suspension, extruded in 5 min was 
measured [10]. E = J(
rv
rp
)2 Where, E = Elasticity of vesicles 
membrane, J = Amount of suspension extruded in 5 min, rv = 
Vesicles size, rp = pore diameter.  
In vitro drug release studies through dialysis membrane 
On the basis of maximum % EE, suitable vesicular size and 
maximum DI F8 was selected for this study. Treated cellophane 
membrane was tied on the mouth of dialysis tube (surface area 4.52 
cm2) and diffusion conditions were maintained. 50 ml of phosphate 
buffer (pH 6.8) was used as receptor fluid at 37 °C at 100 rpm on 
magnetic stirrer. Each of 10 mg IVH-loaded TFs sample from 
selected formulation was placed on cellophane membrane and this 
assembly was touched onto dissolution medium surface. Samples 
were withdrawn (2 ml) at regular intervals of 10 min and replaced 
with same amount of phosphate buffer (pH 6.8). Same procedure 
was adopted for lLF and plain drug (IVH). The samples were suitably 
diluted with buffer solution up to 3 h and absorbance was noted at 
286.0 nm using phosphate buffer (pH 6.8) as blank. The percentage 
drug released was determined as follows- 
% Drug release =  
released amount of drug at time t
Initial amount of drug
X 100 
Morphology of prepared vesicle 
SEM study was carried out on selected formulation TFs-Tween-80 
(F8) and on fLF. 
Formulation of IVH-loaded TFs gel 
The optimized TFs-Tween-80 loaded drug suspension (TFs-TW-80) 
was incorporated in carpobol-940 polymer with PEG-400, PG and 
phosphate buffer solution (pH 6.8) in optimize concentration. The 
formulae for preparing gel using these ingredients were optimized 
according to 32factorial designs [11]. In this design, three levels of 
variables PEG-400 (20, 30, 40% w/w) and PG (15, 20, 25% w/w) 
were taken and the concentrations of carbopol-940 (1.5% w/w) and 
TFs-TW-80 suspension (1.0% w/w) were kept constant and the 
release rate of drug through cellophane membrane of each of nine 
batches was analyzed and the batch having maximum release was 
used for the preparation of aqueous gels. For release rate studies, 
phosphate buffer (pH 6.8) was prepared by I. P. (1996) method. 
Resulting formulae concentration were mixed slowly and kept for 24 
h for proper swelling of polymer to produce a transparent gel. 
Liposome formulation loaded drug (LF) gel was also prepared by 
following same procedure as control [12]. These formulations were 
stored in amber-colored wide-mouth glass containers for further 
studies. 
Characterization of gel 
Determination of pH 
For pH determination, 500 mg TFs-gel and LF-gel were dissolved in 
distilled water and volume made up to 10 ml then pH was 
determined by dipping calibration pH electrode of the pH-meter 
inside the mixture.  
Rheological study of gel 
The viscosities of prepared gels were measured using Brook-field 
Viscometer with spindle no. 4 (Brookfield DV-II+pro viscometer), at 
angular velocities 32.0±0.1 °C. 
Assay and content uniformity 
For this study in gels (TFs and LF) was measured using 
spectrophotometer. Known amount of aqueous gel (500 mg) from 
each of formulation was dissolved separately in phosphate buffer 
(pH 6.8). After suitable dilution and the absorbance was measured 
by UV at 286.0 nm using phosphate buffer (pH 6.8) as blank. The 
drug content was then computed from calibration curve. Random 
sampling of gel at different points from the bulk was carried out for 
the content uniformity in gel by the above procedure [13]. 
Determination of partition coefficient between stratum 
corneum and buffer (pH 6.4) 
It was carried out by mounting a known amount of the sample (1.0 
g) from formulation TFs-gel, LF-gel and plain drug each, on the 
prepared hairless rat skin and allowed to equilibrate for 5 h. 
Receiver compartment was 20 ml buffer (pH 6.4). After 5 h gel was 
scrapped off and drug content was analyzed by UV at 286.0 nm. 
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Amount thus partitioned into skin was calculated as partition 
coefficient [14].  
Ex vivo permeation study 
Drug release studies from gel is an important step during the 
development stages of new formulations for assuring that a drug 
carried by a vehicle is able to reach the skin surface at an adequate 
rate and in sufficient amounts. For this purpose, the release studies 
were performed over 48 h to be sure that the drug is released over a 
long period of time [15]. Male wistar rat (230g) procured from central 
animal house of RKDF University, Bhopal. The rat was kept under 
standard laboratory conditions at 25±2 °C and 55±5% relative 
humidity with a 12 h light/dark cycle. Rat was acclimatized for one 
week and placed in polypropylene cage with free access to standard 
laboratory diet and water. This study was conducted by following 
guidelines of the institutional animal ethics committee of college of 
pharmacy shri satya sai university of technology and medical sciences 
sehore, having approval number COPSSSUTMS/ANIL/19-07. The 
condition of the rat was monitored every day before performing the 
present study. Dorsal fur was removed from back portion of rat ear 
skin with mechanical hair clipper and depilatory cream was applied to 
remove small hair. The skin was immersed in distilled water 
maintained at 60 °C for 2 min. Fatty layers were removed and washed 
with saline and distilled water for use [16]. The permeation studies 
were carried out by using hairless rat skin. Prepared skin was tied on 
the mouth of dialysis tube (surface area 4.52 cm2). 50 ml phosphate 
buffer (pH 6.8) was used as receptor medium in a beaker on magnetic 
stirrer at 100 rpm at 37 °C. One gram of TFs-gel sample was placed on 
the rat skin and assembly was touched on the surface of dissolution 
medium. Sample (2 ml) were withdrawn at regular intervals of 10 min 
up to 4 h and replaced with same amount of buffer. These samples 
were diluted suitably with dilution medium. The percentage 
cumulative drug release was measured at 286.0 nm using UV 
spectrophotometer [17]. The steady state flux of IVH through rat skin 
was determined from the slope of the linear portion of the amount 
permeated per cm2 (Q) versus time graph. For comparison same 
procedure was adopted with LF-gel and plain drug sample. All 
determinations were carried out in triplicate and findings were 
represented as statistical evaluation.  
Stability studies 
The prepared gel formulations were stored in amber colored glass 
vials at 4±2 °C, room temperature (25±2 °C) and 40±2 °C for 60 d. 
After 10, 30 d and 60 d they were evaluated for percentage residual 
drug contents and pH and physical appearance of the formulations. 
For drug content determination known amount (500 mg) of both gel 
formulation (TFs and LF) were dissolved separately in phosphate 
buffer pH 6.8 after suitable dilution and absorbance was measured 
using UV at 286.0 nm. Initial drug content was taken as 100% for 
each of the formulations. The pH of the both gel formulations were 
recorded by using calibrated pH-meter.  
RESULTS AND DISCUSSION 
Transfersomes were formulated using three different HLB values 
(hydrophilic and lipophilic) surfactants, namely SDC, tween-80 and 
span-80. These surfactants are biocompatible and pharmaceutically 
acceptable [18]. Soya phosphatidylcholine was used in different 
concentration as bilayer forming agent to optimize the entrapment 
efficiency of prepared TFs. Phosphate buffer (pH 6.8) with ethanol 
was used as hydrating media because ethanol has a tendency to alter 
barrier property of the intracellular lipoidal route for higher drug 
permeability [19]. Table 1 showed composition formulation of IVH-
loaded TFs by using surfactants and phospholipid and their 
characterization properties. All formulation was found to be turbid 
and colloidal by observing visually due to swallowing of 
phospholipid in hydrating medium as white dense precipitate. The 
suitably diluted sample of each TFs were observed optical 
microscopically, that showed spherical morphology of vesicles. 
There were significant differences in size between TFs consisting 
different surfactants. This size distribution was observed in range of 
114.4 nm to 282.7 nm. The mean vesicular size for liposomes was 
198.4 nm. In general, particle size increased along with surfactants 
having lower HLB value. This related with increment in the surface 
free energy and hydrophilicity or lipophilicity of surfactant. 
Surfactants interacted with lipid head groups in the membrane 
would increase packing density of layer, which could lead to higher 
surface free energy. Thus, due to fusion between lipid bi-layers by 
higher surface free energy leads larger size. Span-80 has strongest 
hydrophobicity than tween-80 and SDC, size expansion is more in 
span-80 TFs [20]. Among of these F8 showed maximum %EE and 
%DI of 78.4±0.94 and 34.9±1.9 respectively. It was observed that in 
F8, %EE was 2.3 times and %DI was 12.5 times greater than LF 
respectively, as control. The results could be explicated as that the 
entrapment of lipophilic and hydrophilic drug into lipid vesicles was 
influenced by drug distribution coefficient between the lipid and 
aqueous phase [21]. 
 












F1 TF-SDC  95:05 170.2 55.9±0.26 25.3±1.8 Turbid and colloidal 
F2 TF-SDC  90:10 177.3 57.1±0.17 30.1±2.2 Turbid and colloidal 
F3 TF-SDC  85:15 184.8 61.7±0.95 31.7±2.1 Turbid and colloidal 
F4 TF-SDC  80:20 187.7 60.1±1.07 24.2±1.7 Less turbid and colloidal 
F5 TF-SDC  75:25 189.1 53.2±0.92 21.5±1.2 Less colloidal 
F6 TF-TW-80 95:05 114.4 58.5±0.63 22.6±1.4 Turbid and colloidal 
F7 TF-TW-80 90:10 121.9 64.8±0.41 31.7±1.3 Turbid and colloidal 
F8 TF-TW-80 85:15 128.6 78.4±0.94 34.9±1.9 Dense and colloidal 
F9 TF-TW-80 80:20 134.5 76.3±1.08 23.2±1.6 Less turbid and colloidal 
F10 TF-TW-80 75:25 141.8 71.5±0.99 10.8±0.7 Less colloidal 
F11 TF-S-80 95:05 264.9 44.8±0.41 12.4±1.5 Turbid and colloidal 
F12 TF-S-80 90:10 269.2 45.2±0.91 14.3±1.1 Turbid and colloidal 
F13 TF-S-80 85:15 273.5 47.3±0.83 16.8±1.6 Dense and colloidal 
F14 TF-S-80 80:20 278.3 41.8±0.93 09.5±1.3 Less turbid and colloidal 
F15 TF-S-80 75:25 282.7 37.2±1.02 05.3±0.7 Less colloidal 
LF Liposome 
(control) 
 198.4 34.3±1.21 2.8±1.3 Turbid and colloidal 
SPC: SF = soya phosphatidylcholine: surfactant ratio, TF-S-80 = Transfersomes with span-80, TF-TW80 = Transfersomes with tween-80, TF-SDC = 
Transfersomes with sodium deoxycholate Values represented as mean±SD (n = 3),  
 
On the basis of characterization evaluation of prepared TFs due to 
maximum %EE, DI and smaller mean vesicular size F8 was selected for 
In vitro drug release studies through the dialysis membrane. This was 
compared with LF and plain drug (fig. 1). Data revealed that these 
followed firstly first-order kinetics than zero-order kinetics. Percentage 
cumulative drug released in F8 was found to be maximum (89.5±0.12 
%) in 20 min than others. It was 2.1 times higher
higher than plain drug. Vesicles with smaller diameter are believed to 
have larger surface area to release a higher concentr
 
Fig. 1: In vitro percentage 
 
Thus, the selected optimized drug carrier TFs
characterization was used to develop gel with carbopol
phosphate buffer (pH 6.8) in optimized concentration. The formula for 
the development of gel was optimized according to 3
(table 2) and results revealed that there is maximum drug release in 
batch No.5 in both gel preparations (TFs and LF) after two hours. The 
optimized formula thus comprises of-PEG-400 (30% w/w); PG (20% 
w/w); TFs/lF suspension (1.0% w/w); Carbopol
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 than LF and 3.3 times 
ation of drug. 
Prepared TFs of tween-80 with IVH had smaller size and 
affinity towards its hydrophilicity
liposome (LF) indicated the spherical shape (fig. 2 
 
cumulative drug release via dialysis membrane of vesicles 
 
 
Fig. 2: SEM study of formulation F8 (mean±SEM) 
 
 
Fig. 3: SEM study of formulation LF (mean±SEM) 
-TW-80 vesicle after 
-940, PEG, PG, 
2factorial designs 
-940 (1.5% w/w); 
phosphate buffer (pH 6.8) q. s. to (100.0% w/w). A second
polynomial equation was derived from the results of all nine batches. y 
= bo+b1+x1+b2x2+b3x12+b4x22+
response (drug release at 2 h). The main effect (x
average results of changing one factor at a time from its low to high 
value. The interaction (x1x2) shows the response changes with 
combined effect of factors. The coefficients corresponding to linear 




. SEM study of Tween-80 TFs (F8) and 
and fig. 3). 
(mean±SD, n=3) 
-order 
b5x1x2. In the equation y is the 
1, x2) represents the 
the 
) and quadrate effect (b3, b4) were 
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determined from the results of the experiments (table 3). The fitted 
equation relating to the percent drug released in 2 h. (y) to 
transformed factor as follows: for LF-gel the equation is: Y(LF) = [5.2–
6.98 x 10-2x1–1.43 x2x 10-1+1.62x12+3.78 x 10-2x22–1.04 x1x2] x 10-
2and for F1-gel the equation is: Y (TFs) = [5.5–1.28 x1-0.511 x2+0.129 
x12+0.806 x22-0.250 x1x2] x 10-2, [22]. 
 
Table 2: Detail layout of 32 factorial designs to study the effect of variables on transdermal permeation using cellophane membrane 
Batch No. Values for variables % drug released within 20 min with 
PG (% w/w) (x1) PEG-400 (% w/w) (x2)  LF-gel TFs-gel 
1 15 (-1) 20 (-1) 38.3±0.04 41.1±0.21 
2 15 (-1) 30 (0) 39.8±0.11 45.5±0.03 
3 15 (-1) 40 (1) 41.3±0.08 48.8±0.11 
4 20 (0) 20 (-1) 43.4±0.31 52.2±0.14 
5 20 (0) 30 (0) 48.2±0.21 78.3±0.04 
6 20 (0) 40 (1) 42.1±0.09 69.5±0.06 
7 25 (1) 20 (-1) 37.2±1.02 53.3±0.22 
8 25 (1) 30 (0) 36.1±0.07 51.1±0.31 
9 25 (1) 40 (1) 34.5±0.02 47.9±0.08 
The % drug release values are expressed as mean±SD=standard deviation from mean, n=3 
 
Table 3: Analyzed values for different variables 
 Values p-value Standard Error 
LF-gel TFs-gel LF-gel TFs-gel LF-gel TFs-gel 
bo 0.05275 0.05483 0.00124 0.000821 0.00439 0.00397 
b1 -0.000698 -0.01267 0.796 0.01003 0.00341 0.00217 
b2 -0.00143 -0.00511 0.573 0.1063 0.00243 0.00289 
b3 0.01620 0.00124 0.0506 0.754 0.00471 0.00312 
b4 0.000378 0.00803 0.745 0.1221 0.00366 0.00256 
b5 -0.01041 -0.00641 0.03869 0.417 0.00293 0.00284 
 The values are expressed as mean of three trials (n=3)  
 
The pH of prepared TFs-gel and LF-gel was maintained at 6.4 as per 
the skin pH. The rheological behavior of the gel formulation is 
governed by its components and its consistency. Viscosities of TFs-
gel and LF-gel were found to be 11506.33±2.08 cps and 
12514.72±1.81 cps, respectively.  
Prepared gels were evaluated for percent drug content as per the 
pharmacopoeial specification for topical preparation. The drug 
contents in the TFs and LF gels were found to be 92 to 95% w/w. 
The drug was found uniformly distributed in gels. The stratum 
corneum (SC) is a multilayered wall-like structure in which keratin-
rich corneocytes are embedded in an inter-cellular lipid-rich matrix, 
which acts as a permeation barrier for the transdermal delivery of 
most drugs [23]. SC is the first and main barrier for drug permeation 
through skin need the partitioning of the drug. It was observed that 
IVH alone, TFs and LF-gel have partition coefficient (KSc/buffer) of 
4.30±0.07, 1.04±0.03 and 3.11±0.21, respectively. Data suggested that 
the KSc/buffer had increased by dense phospholipid bilayer in 
liposome structure than IVH drug alone. Due to hydrophilicity of drug 
IVH, it partitioned better through skin than liposome. Formulation 
TFs-gel showed good portioning results due to the flexible behavior of 
its components and the deformability character of TFs.  
Ex vivo permeation study from hairless rat skin revealed that the 
percent cumulative released of formulation TFs-gel, LF-gel and IVH 
alone were 73.5±0.14%, 43.1±0.05% and 37.2±0.12% respectively 
after twenty minutes (table 4). Fig. 4 showed that a linear relationship 
was obtained when the cumulative percentage release was plotted 
against time up to twenty minutes. This permeation of drug is 
described by firstly first-order kinetics than zero-order kinetics. The 
drug released from TFs-gel was found to be 1.7 times higher than LF-
gel and about 1.9 times higher than the plain drug. The release profiles 
of IVH from gels showed biphasic release processes where initial burst 
release of the surface-adsorbed drug was observed, followed by slow 
diffusion from the lipid vesicles. At the initial hour, the little higher 
drug release of LF-gel was observed. This could be attributed to more 
unentrapped drug distribution in the gel system as liposomes had a 
lower percentage of entrapment efficiency (%EE). Unentrapped drugs 
could pass through the release interface earlier compared with drugs 
entrapped in vesicles. Afterward, lipid vesicles diffusion in gels played 
an important role in the release profiles and the drug release rate 
slowed down. TFs with higher %EE and better deformability could 
carry more drugs through filters quickly as compared with liposomes 
and plain drug. The amount of drug permeated per cm2 (Q) against 
time revealed the flux. The slope of the linear portion of graph 
revealed flux up to 30 min (table 5 and fig. 5). Results concluded that 
the liposomes would rupture while squeezing the nano-pores, which 
were much smaller than vesicles sizes due to their rigid structures. 
They carried fewer amounts of applied drug into the deeper layer. TFs 
could be released from gel system and overcome the nano-porous 
barrier to follow the natural water gradient across the epidermis by 
the greater flexibility and movement of the bilayer. Then more drugs 
would be transferred to deeper skin [24]. 
 
Table 4: In vitro percentage of cumulative drugs released through hairless rat skin 
S. No. Time (min) Plain drug LF-gel TFs-gel 
1 10 17.8±0.07 37.2±0.04 62.1±0.06 
2 20 37.2±0.12 43.1±0.05 73.5±0.14 
3 30 39.7±0.31 45.7±0.11 76.8±0.03 
4 40 41.3±0.09 49.5±0.40 80.1±0.12 
5 50 42.4±0.11 50.8±0.06 82.2±0.32 
6 60 43.1±0.20 51.2±0.22 83.1±0.03 
7 120 44.6±0.13 51.5±0.12 83.4±0.02 
8 180 44.9±0.18 52.2±0.15 84.2±0.11 




S. No.  Formulation 
 1 Plain drug 
 2 TFs-gel 
 3 LF-gel 
Area of membrane used = 4.52 cm2, The values are expressed as mean±SD=standard 
 
Fig.
The storage stability testing was carried out for both gel formulations by 
the measurement of residual drug content, pH and physical appearance 
after storing at 4±2 °C, room temperature (25±2 
10, 30 and 60 d. The percent residual drug content
formulations were shown in table 6. There are changes in drug content 
over 2 mo for the stored formulations at 40±2 
findings of the stability study suggested that the storage of TFs
and room temperature may enhance stability of trans
 
Formulation Time (After days)
TFs-Gel  



















*The values are expressed as mean±SD=standard deviation from mean, n=3
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: Flux of different formulations through hairless rat skin 




deviation from mean, n=3
 5: Flux of different formulations (mean±SD, n=3) 
 
°C) and 40±2 °C after 
 and pH of 
°C was observed. The 
 at 4±2 °C 
fersomes. 
Embedding TFs into gel may support stability of trans
as a result of increasing viscosity of the carrier, reducing 
of infusion. The pH of the formul
and room temperature as no changes in appearance w
higher temperature showed instability 
after 60 d. This indicated that the suitable
formulations is temperature 25 
therapeutic efficacy of formulations
Table 6: Stability studies of prepared gels* 
 Temperature at 

























ation was found to be stable at 4±2 °C 
ere detected and 
as hard texture was observed 
 storage condition for the 
°C or less, where the pH, potency and 
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CONCLUSION 
It was concluded that IVH-transfersomes formulated by using 
tween-80: soya lecithin (15: 85) showed highest %EE, highest DI, 
suitable vesicle size and maximum % cumulative drug release 
through dialysis membrane than others vesicular formulations. 
Evaluated IVH loaded tween-80 TFs were used to formulate gel by 
using carbopol-940 and permeation enhancers (PEG-400, PG) for 
transdermal delivery. Prepared gel was compared with liposomal 
gel and found that TFs are more suitable drug carrier than liposome 
due to its excellent deformability behavior and can transfer 0.1 mg 
of lipid per hour per cm2 area by osmotic gradient. Stability of IVH 
was increased by incorporation of TFs in polymer. Thus, IVH loaded 
TFs are the excellent carrier for transdermal drug delivery because 
of topical delivery avoids hepatic first-pass effect, overcome side 
effects associated with oral route and improves bioavailability, 
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